Characteristics | Reports,no(%) |
---|---|
Reporting region | |
 Europe | 222 (81.3) |
 Asian | 24 (8.8) |
 North America | 18 (6.6) |
 Oceania | 2 (0.7) |
 Unspecified | 7 (2.6) |
Reporters | |
 Healthcare professionals | 234 (85.7) |
 Non-healthcare professionals | 13 (4.8) |
 Unspecified | 26 (9.5) |
Reporting year | |
 2019 | 72 (26.4) |
 2018 | 33 (12.1) |
 2017 | 32 (11.7) |
 2016 | 20 (7.3) |
 2015 | 24 (8.8) |
 2014 | 13 (4.8) |
 2013 | 11 (4.0) |
 2012 | 11 (4.0) |
 2011 | 27 (9.9) |
 2010 | 7 (2.6) |
 2009 | 4 (1.5) |
 2008 | 3 (1.1) |
 2007 | 3 (1.1) |
 2006 | 4 (1.5) |
 2005 | 6 (2.2) |
 2004 | 3 (1.1) |
Sex of patients | |
 Male | 114 (48.7) |
 Female | 133 (41.8) |
 Unknown or missing | 26 (9.5) |
Age groups (years) | |
 <18 | 2 (0.7) |
 18–44 | 4 (1.5) |
 45–64 | 28 (10.3) |
 65–74 | 71 (26.0) |
 75–84 | 82 (30.0) |
  ≥ 85 | 41 (15.0) |
 Unknown or missing | 45 (16.5) |
PPIs as suspected drugs | |
 Omeprazole | 122 (44.7) |
 Lansoprazole | 43 (15.8) |
 Pantoprazole | 64 (23.4) |
 Rabeprazole | 10 (3.7) |
 Esomeprazole | 34 (12.5) |
 Dexlansoprazole | 0 (0.0) |
Indications for tumors of different sites | |
 Gastroesophageal reflux disease | 37 (17.1) |
 Peptic ulcer disease | 14 (6.5) |
 Gastroduodenitis | 10 (4.6) |
 Functional dyspepsia | 9 (4.2) |
 Epigastric pain or discomfort | 7 (3.2) |
 Non-specified gastrointestinal disorders | 4 (1.9) |
 Eradication of Helicobacter pylori infection | 4 (1.9) |
 Peptic ulcer-related gastrointestinal bleeding | 2 (0.9) |
 Lower abdominal discomfort | 2 (0.9) |
 Esophagitis | 1 (0.5) |
 Other indications | 28 (13.0) |
 Unknown or missing indications | 98 (45.4) |